OPEN journal publications

Below is our growing list of published and in-press journal publications. Where possible, we have linked paper titles to the full articles.all OPEN journal papers as of September 2016

  1. Farrell B, Richardson L, Raman-Wilms L, de Launay D, Alsabbagh MW, Conklin J. Self-efficacy for deprescribing: A survey for health care professionals using evidence-based deprescribing guidelinesRes Social Adm Pharm, 2018 14(1):18–25.
  2. Patel T, Slonim K, Lee L. Use of potentially inappropriate medications among ambulatory home-dwelling elderly patients with dementia: A review of the literature. Can Pharm J, 2017;150(3):169–83.
  3. Farrell B, Pottie K, Thompson W, Boghossian T, Pizzola L, Rashid FJ, Rojas-Fernandez C, Walsh K,  Welch V, Moayyedi, P. Deprescribing proton pump inhibitors: Evidence-based clinical practice guidelineCan Fam Phys, May 2017, 63(5):354–64.
  4. MacCallum L, Consiglio G, MacKeigan L, Dolovich L. Uptake of community pharmacist-delivered MedsCheck Diabetes medication review service in Ontario between 2010 and 2014. Can J Diabetes. March 17, 2017. [Epub ahead of print] doi: 10.1016/j.jcjd.2016.12.001.
  5. Thompson W, Quay TA, Rojas-Fernandez C, Farrell B, Bjerre LM. Atypical antipsychotics for insomnia: a systematic review. Sleep Med, 2016;22:13–7.
  6. Pechlivanoglou P, Abrahamyan L, MacKeigan L, Consiglio GP, Dolovich L, Li P, Cadarette SM, Rac VE, Shin J, Krahn M. Factors affecting the delivery of community pharmacist-led medication reviews: evidence from the MedsCheck annual service in OntarioBMC Health Serv Res, 2016;16(1):666.
  7. Dolovich L, Consiglio G, MacKeigan L, Abrahamyan L, Pechlivanoglou P, Rac VE, Pojskic N, Bojarski EA, Su J, Krahn M, Cadarette SM. Uptake of the MedsCheck annual medication review service in Ontario community pharmacies between 2007 and 2013. Can Pharm J, 2016;149(5):293–302.
  8. Dolovich L, Tsuyuki RT. Pharmacy practice research produces findings that inform how pharmacists contribute to optimal drug therapy outcomes for Canadians. Can Pharm J, 2016;149(5):261–3.
  9. Farrell B, Pottie K, Rojas-Fernandez CH, Bjerre LM, Thompson W, Welch V. Methodology for developing deprescribing guidelines: Using evidence and GRADE to guide recommendations for deprescribing. PLoS One, 2016;11(8): e0161248. doi:10.1371/journal.pone.016124.
  10. Thompson W, Hogel M, Li Y, Thavorn K, O’Donnell D, McCarthy L, Dolovich L Black C, Farrell B. Effect of a proton pump inhibitor deprescribing guideline on drug usage and costs in long-term care. JAMDA, 2016, in press, doi.org/10.1016/j.jamda.2016.04.020.
  11. Patel T, Chang F, Mohammed HT, Raman-Wilms L, Jurcic J, Khan A, Sproule B. Knowledge, perceptions and attitudes toward chronic pain and its management: A cross-sectional survey of frontline pharmacists in Ontario, Canada. PLOS One, 2016;11(6):e0157151. doi:10.1371/journal. pone.0157151.
  12. Ziegler B, Alsabbagh W, Houle S, Wenger L, Church D, Waite N. Protecting our patients by protecting ourselves: An analysis of the personal influenza immunization rate of Ontario community pharmacists. Can Pharm J, 2016; 149(4):246–55.
  13. Church D, Johnson S, Raman-Wilms L, Schneider E, Waite N, Pearson-Sharpe J. A literature review of the impact of pharmacy students in immunization initiatives. Can Pharm J. 2016;149(3):153–65.
  14. Famiyeh IM, McCarthy L. Pharmacist prescribing: A scoping review about the views and experiences of patients and the public. Res Social Adm Pharm. 2016 Jan 18. doi:10.1016/j.sapharm.2016.01.002 [Epub ahead of print].
  15. Boghossian TA, Rashid FJ, Welch V, Rojas-Fernandez C, Moayyedi P, Pottie K, Walsh K, Pizzola L, Thompson W, Farrell B. Deprescribing versus continuation of chronic proton pump inhibitor use in adults (protocol). Cochrane Database Syst Rev, 2015; Issue 11, article number CD011969.
  16. Lee R, McCarthy L. Canadian “minor ailments” programs: Unanswered questions. Can Pharm J, 2015;148(6):302–4.
  17. Wenger LM, Rosenthal M, Sharpe JP, Waite N. Confronting inequities: A scoping review of the literature on pharmacist practice and health-related disparities. Res Social Adm Pharm. 2016;12(2):175–217.
  18. Conklin J, Farrell B, Ward N, McCarthy L, Irving H, Raman-Wilms L. Developmental evaluation as a strategy to enhance the uptake and use of deprescribing guidelines: protocol for a multiple case study. Implement Sci, 2015 Jun 18;10(1):91. doi: 10.1186/s13012-015-0279-0.
  19. Farrell B, Tsang C, Raman-Wilms L, Irving H, Conklin J, Pottie K. What are priorities for deprescribing for elderly patients? Capturing the voice of practitioners: A modified Delphi process. PLOS One, 2015; 10(4):e0122246.
  20. Wong L, Burden AM, Liu YY, Tadrous M, Pojskic N, Dolovich L, Calzavara A, Cadarette SM. Initial uptake of the Ontario Pharmacy Smoking Cessation Program: Descriptive analysis over 2 years. Can Pharm J, 2015;148(1):29–40.
  21. Thompson W, Farrell B. Deprescribing: What is it and what does the evidence tell us? Canadian Journal of Hospital Pharmacy, 2013; 66(3):201–2.